A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. / Mocroft, A; Reiss, P; Rakhmanova, A; Banhegyi, D; Phillips, A N; De Wit, S; Ristola, M; Lundgren, J D; Grarup, J; Kirk, O; EuroSIDA in EuroCoord.

I: Infection: A Journal of Infectious Diseases, Bind 42, Nr. 4, 08.2014, s. 757-762.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Mocroft, A, Reiss, P, Rakhmanova, A, Banhegyi, D, Phillips, AN, De Wit, S, Ristola, M, Lundgren, JD, Grarup, J, Kirk, O & EuroSIDA in EuroCoord 2014, 'A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe', Infection: A Journal of Infectious Diseases, bind 42, nr. 4, s. 757-762. https://doi.org/10.1007/s15010-014-0630-4

APA

Mocroft, A., Reiss, P., Rakhmanova, A., Banhegyi, D., Phillips, A. N., De Wit, S., Ristola, M., Lundgren, J. D., Grarup, J., Kirk, O., & EuroSIDA in EuroCoord (2014). A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection: A Journal of Infectious Diseases, 42(4), 757-762. https://doi.org/10.1007/s15010-014-0630-4

Vancouver

Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, De Wit S o.a. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection: A Journal of Infectious Diseases. 2014 aug.;42(4):757-762. https://doi.org/10.1007/s15010-014-0630-4

Author

Mocroft, A ; Reiss, P ; Rakhmanova, A ; Banhegyi, D ; Phillips, A N ; De Wit, S ; Ristola, M ; Lundgren, J D ; Grarup, J ; Kirk, O ; EuroSIDA in EuroCoord. / A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. I: Infection: A Journal of Infectious Diseases. 2014 ; Bind 42, Nr. 4. s. 757-762.

Bibtex

@article{380793d54f4e4f50838e63a54fdec1c0,
title = "A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe",
abstract = "ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥ 3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.",
keywords = "Adenine, Adult, Anti-HIV Agents, Cohort Studies, Data Collection, Deoxycytidine, Drug Combinations, Drug Utilization, Europe, Female, HIV Infections, Humans, Male, Organophosphonates, Oxazines, Prospective Studies",
author = "A Mocroft and P Reiss and A Rakhmanova and D Banhegyi and Phillips, {A N} and {De Wit}, S and M Ristola and Lundgren, {J D} and J Grarup and O Kirk and {EuroSIDA in EuroCoord}",
year = "2014",
month = aug,
doi = "10.1007/s15010-014-0630-4",
language = "English",
volume = "42",
pages = "757--762",
journal = "Therapies",
issn = "0300-8126",
publisher = "Springer Medizin",
number = "4",

}

RIS

TY - JOUR

T1 - A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

AU - Mocroft, A

AU - Reiss, P

AU - Rakhmanova, A

AU - Banhegyi, D

AU - Phillips, A N

AU - De Wit, S

AU - Ristola, M

AU - Lundgren, J D

AU - Grarup, J

AU - Kirk, O

AU - EuroSIDA in EuroCoord

PY - 2014/8

Y1 - 2014/8

N2 - ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥ 3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

AB - ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥ 3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

KW - Adenine

KW - Adult

KW - Anti-HIV Agents

KW - Cohort Studies

KW - Data Collection

KW - Deoxycytidine

KW - Drug Combinations

KW - Drug Utilization

KW - Europe

KW - Female

KW - HIV Infections

KW - Humans

KW - Male

KW - Organophosphonates

KW - Oxazines

KW - Prospective Studies

U2 - 10.1007/s15010-014-0630-4

DO - 10.1007/s15010-014-0630-4

M3 - Journal article

C2 - 24902520

VL - 42

SP - 757

EP - 762

JO - Therapies

JF - Therapies

SN - 0300-8126

IS - 4

ER -

ID: 137311036